Posted by Michael Wonder on 14 Feb 2022
Bavarian Nordic announces breakthrough therapy designation for its RSV vaccine candidate for the prevention of respiratory syncytial virus in older adults
14 February 2022 - Bavarian Nordic announced today that the U.S. FDA has granted breakthrough therapy designation for the Company's vaccine candidate, MVA-BN RSV, for active immunisation for prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 years or older.
The vaccine candidate is based on Bavarian Nordic’s proprietary MVA-BN platform technology, also used in the Company’s approved vaccines for smallpox and Ebola.
Bavarian Nordic plans to initiate a large Phase 3 trial of MVA-BN RSV in 2022.
